Loading…

Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation

Real-world data (RWD) and real-world evidence (RWE) appear now as complementary to traditional randomized controlled trials (RCT), that remain the gold standard of the evidence. This review aims to illustrate how health authorities in France, United States (USA) and United Kingdom (UK) can integrate...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic innovation & regulatory science 2021, Vol.55 (1), p.228-238
Main Authors: Pulini, Alfredo Aram, Caetano, Gabriela Martins, Clautiaux, Henri, Vergeron, Laure, Pitts, Peter J., Katz, Gregory
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3
cites cdi_FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3
container_end_page 238
container_issue 1
container_start_page 228
container_title Therapeutic innovation & regulatory science
container_volume 55
creator Pulini, Alfredo Aram
Caetano, Gabriela Martins
Clautiaux, Henri
Vergeron, Laure
Pitts, Peter J.
Katz, Gregory
description Real-world data (RWD) and real-world evidence (RWE) appear now as complementary to traditional randomized controlled trials (RCT), that remain the gold standard of the evidence. This review aims to illustrate how health authorities in France, United States (USA) and United Kingdom (UK) can integrate RWD and RWE in market authorization discussions and in new pathways of price and reimbursement negotiations. We conducted a review from the literature, online investigations and interviews. RWD and RWE can be valuable in the context of market access, reimbursement decisions, price negotiation, pharmacovigilance and positive patient outcomes. While RWD could open new areas of innovative approaches and improve the efficiency of health systems, they have methodological limitations requiring further analysis to reach a sufficient level of proof. Moreover, misleading use of “RWD” and “RWE” terms is very frequent and even the definitions used by stakeholders (when they have one) are heterogenous. Because of the intrinsic characteristics of each product, the value given to these RWD may differ a lot, making them a useful tool more than an indispensable one. In sum, RWD and, more precisely, RWE have the potential to bring value to the health system at every step of the drug development process, from the discovery to the pharmacovigilance phase.
doi_str_mv 10.1007/s43441-020-00208-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2438683570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475491770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonR6ETnBVwYEhPjwioUOtClmfGWjJcYjStDKD3Vjm0ZgS706cUZL4kLWcAJfOfn5ENom5JDSog48pxxThOSkoTETSZ0BQ1SOpIJl4SvftciJxto6P2MxJXLTKRyHW2wNFaMsgF6vGjn2gRsK3wLukkerGtKPNFBY9vhS-1eIODjPjxbV7_rUNvuIIJ1W_TOQwtdwBMwtY_3eA_fuNoAvoInG-oFu4XWKt14GH6dm-j-9ORufJ5Mr88uxsfTxDCRhSQXBRRCpFmWUxjlJWOVkVyaODItDC1IVVFhMiZNxVKWy4KORFmCLDlhBDLNNtH-Mnfu7GsPPqi29gaaRndge69SzuRIskyQiO7-QWe2d12cLlIi4zkVCypdUsZZ7x1Uau7qVrs3RYn69K-W_lVUrxb-FY1NO1_RfdFC-dPybTsCbAn4-NQ9gfv9-5_YDwNyjmI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475491770</pqid></control><display><type>article</type><title>Impact of Real-World Data on Market Authorization, Reimbursement Decision &amp; Price Negotiation</title><source>Springer Nature</source><creator>Pulini, Alfredo Aram ; Caetano, Gabriela Martins ; Clautiaux, Henri ; Vergeron, Laure ; Pitts, Peter J. ; Katz, Gregory</creator><creatorcontrib>Pulini, Alfredo Aram ; Caetano, Gabriela Martins ; Clautiaux, Henri ; Vergeron, Laure ; Pitts, Peter J. ; Katz, Gregory</creatorcontrib><description>Real-world data (RWD) and real-world evidence (RWE) appear now as complementary to traditional randomized controlled trials (RCT), that remain the gold standard of the evidence. This review aims to illustrate how health authorities in France, United States (USA) and United Kingdom (UK) can integrate RWD and RWE in market authorization discussions and in new pathways of price and reimbursement negotiations. We conducted a review from the literature, online investigations and interviews. RWD and RWE can be valuable in the context of market access, reimbursement decisions, price negotiation, pharmacovigilance and positive patient outcomes. While RWD could open new areas of innovative approaches and improve the efficiency of health systems, they have methodological limitations requiring further analysis to reach a sufficient level of proof. Moreover, misleading use of “RWD” and “RWE” terms is very frequent and even the definitions used by stakeholders (when they have one) are heterogenous. Because of the intrinsic characteristics of each product, the value given to these RWD may differ a lot, making them a useful tool more than an indispensable one. In sum, RWD and, more precisely, RWE have the potential to bring value to the health system at every step of the drug development process, from the discovery to the pharmacovigilance phase.</description><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1007/s43441-020-00208-1</identifier><identifier>PMID: 32857313</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Clinical trials ; Drug development ; Drug Safety and Pharmacovigilance ; Literature reviews ; Medicine ; Negotiations ; Pharmacology ; Pharmacotherapy ; Pharmacovigilance ; Pharmacy ; Review</subject><ispartof>Therapeutic innovation &amp; regulatory science, 2021, Vol.55 (1), p.228-238</ispartof><rights>The Drug Information Association, Inc 2020</rights><rights>The Drug Information Association, Inc 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3</citedby><cites>FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3</cites><orcidid>0000-0002-1027-4537</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32857313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pulini, Alfredo Aram</creatorcontrib><creatorcontrib>Caetano, Gabriela Martins</creatorcontrib><creatorcontrib>Clautiaux, Henri</creatorcontrib><creatorcontrib>Vergeron, Laure</creatorcontrib><creatorcontrib>Pitts, Peter J.</creatorcontrib><creatorcontrib>Katz, Gregory</creatorcontrib><title>Impact of Real-World Data on Market Authorization, Reimbursement Decision &amp; Price Negotiation</title><title>Therapeutic innovation &amp; regulatory science</title><addtitle>Ther Innov Regul Sci</addtitle><addtitle>Ther Innov Regul Sci</addtitle><description>Real-world data (RWD) and real-world evidence (RWE) appear now as complementary to traditional randomized controlled trials (RCT), that remain the gold standard of the evidence. This review aims to illustrate how health authorities in France, United States (USA) and United Kingdom (UK) can integrate RWD and RWE in market authorization discussions and in new pathways of price and reimbursement negotiations. We conducted a review from the literature, online investigations and interviews. RWD and RWE can be valuable in the context of market access, reimbursement decisions, price negotiation, pharmacovigilance and positive patient outcomes. While RWD could open new areas of innovative approaches and improve the efficiency of health systems, they have methodological limitations requiring further analysis to reach a sufficient level of proof. Moreover, misleading use of “RWD” and “RWE” terms is very frequent and even the definitions used by stakeholders (when they have one) are heterogenous. Because of the intrinsic characteristics of each product, the value given to these RWD may differ a lot, making them a useful tool more than an indispensable one. In sum, RWD and, more precisely, RWE have the potential to bring value to the health system at every step of the drug development process, from the discovery to the pharmacovigilance phase.</description><subject>Clinical trials</subject><subject>Drug development</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Literature reviews</subject><subject>Medicine</subject><subject>Negotiations</subject><subject>Pharmacology</subject><subject>Pharmacotherapy</subject><subject>Pharmacovigilance</subject><subject>Pharmacy</subject><subject>Review</subject><issn>2168-4790</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOxCAUhonR6ETnBVwYEhPjwioUOtClmfGWjJcYjStDKD3Vjm0ZgS706cUZL4kLWcAJfOfn5ENom5JDSog48pxxThOSkoTETSZ0BQ1SOpIJl4SvftciJxto6P2MxJXLTKRyHW2wNFaMsgF6vGjn2gRsK3wLukkerGtKPNFBY9vhS-1eIODjPjxbV7_rUNvuIIJ1W_TOQwtdwBMwtY_3eA_fuNoAvoInG-oFu4XWKt14GH6dm-j-9ORufJ5Mr88uxsfTxDCRhSQXBRRCpFmWUxjlJWOVkVyaODItDC1IVVFhMiZNxVKWy4KORFmCLDlhBDLNNtH-Mnfu7GsPPqi29gaaRndge69SzuRIskyQiO7-QWe2d12cLlIi4zkVCypdUsZZ7x1Uau7qVrs3RYn69K-W_lVUrxb-FY1NO1_RfdFC-dPybTsCbAn4-NQ9gfv9-5_YDwNyjmI</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Pulini, Alfredo Aram</creator><creator>Caetano, Gabriela Martins</creator><creator>Clautiaux, Henri</creator><creator>Vergeron, Laure</creator><creator>Pitts, Peter J.</creator><creator>Katz, Gregory</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1027-4537</orcidid></search><sort><creationdate>2021</creationdate><title>Impact of Real-World Data on Market Authorization, Reimbursement Decision &amp; Price Negotiation</title><author>Pulini, Alfredo Aram ; Caetano, Gabriela Martins ; Clautiaux, Henri ; Vergeron, Laure ; Pitts, Peter J. ; Katz, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical trials</topic><topic>Drug development</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Literature reviews</topic><topic>Medicine</topic><topic>Negotiations</topic><topic>Pharmacology</topic><topic>Pharmacotherapy</topic><topic>Pharmacovigilance</topic><topic>Pharmacy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pulini, Alfredo Aram</creatorcontrib><creatorcontrib>Caetano, Gabriela Martins</creatorcontrib><creatorcontrib>Clautiaux, Henri</creatorcontrib><creatorcontrib>Vergeron, Laure</creatorcontrib><creatorcontrib>Pitts, Peter J.</creatorcontrib><creatorcontrib>Katz, Gregory</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic innovation &amp; regulatory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pulini, Alfredo Aram</au><au>Caetano, Gabriela Martins</au><au>Clautiaux, Henri</au><au>Vergeron, Laure</au><au>Pitts, Peter J.</au><au>Katz, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Real-World Data on Market Authorization, Reimbursement Decision &amp; Price Negotiation</atitle><jtitle>Therapeutic innovation &amp; regulatory science</jtitle><stitle>Ther Innov Regul Sci</stitle><addtitle>Ther Innov Regul Sci</addtitle><date>2021</date><risdate>2021</risdate><volume>55</volume><issue>1</issue><spage>228</spage><epage>238</epage><pages>228-238</pages><issn>2168-4790</issn><eissn>2168-4804</eissn><abstract>Real-world data (RWD) and real-world evidence (RWE) appear now as complementary to traditional randomized controlled trials (RCT), that remain the gold standard of the evidence. This review aims to illustrate how health authorities in France, United States (USA) and United Kingdom (UK) can integrate RWD and RWE in market authorization discussions and in new pathways of price and reimbursement negotiations. We conducted a review from the literature, online investigations and interviews. RWD and RWE can be valuable in the context of market access, reimbursement decisions, price negotiation, pharmacovigilance and positive patient outcomes. While RWD could open new areas of innovative approaches and improve the efficiency of health systems, they have methodological limitations requiring further analysis to reach a sufficient level of proof. Moreover, misleading use of “RWD” and “RWE” terms is very frequent and even the definitions used by stakeholders (when they have one) are heterogenous. Because of the intrinsic characteristics of each product, the value given to these RWD may differ a lot, making them a useful tool more than an indispensable one. In sum, RWD and, more precisely, RWE have the potential to bring value to the health system at every step of the drug development process, from the discovery to the pharmacovigilance phase.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32857313</pmid><doi>10.1007/s43441-020-00208-1</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1027-4537</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2168-4790
ispartof Therapeutic innovation & regulatory science, 2021, Vol.55 (1), p.228-238
issn 2168-4790
2168-4804
language eng
recordid cdi_proquest_miscellaneous_2438683570
source Springer Nature
subjects Clinical trials
Drug development
Drug Safety and Pharmacovigilance
Literature reviews
Medicine
Negotiations
Pharmacology
Pharmacotherapy
Pharmacovigilance
Pharmacy
Review
title Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Real-World%20Data%20on%20Market%20Authorization,%20Reimbursement%20Decision%20&%20Price%20Negotiation&rft.jtitle=Therapeutic%20innovation%20&%20regulatory%20science&rft.au=Pulini,%20Alfredo%20Aram&rft.date=2021&rft.volume=55&rft.issue=1&rft.spage=228&rft.epage=238&rft.pages=228-238&rft.issn=2168-4790&rft.eissn=2168-4804&rft_id=info:doi/10.1007/s43441-020-00208-1&rft_dat=%3Cproquest_cross%3E2475491770%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-97beb7725591e69d33fc848c0001bc1b0ff17c538cf32398b167dde8d4030e5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2475491770&rft_id=info:pmid/32857313&rfr_iscdi=true